

**From Acting Chief Pharmaceutical Officer
Mrs Cathy Harrison**



To:
Chief Executives, HSC Trusts (*for onward distribution to all relevant staff*)
Chief Executive, PHA
Chief Executive, HSCB (*for onward distribution to community pharmacy contractors, General Practitioners, Practice Managers, GP Locums and GP Out of Hours Services for onward distribution to practice staff*)

Castle Buildings
Stormont
Belfast
BT4 3SQ
Tel: 028 90 523219
Email: cathy.harrison@health-ni.gov.uk

Date: 4th February 2019

[By email]

Dear Colleague,

NORTHERN IRELAND DRUG TARIFF: WOUND CARE MANAGEMENT PRODUCTS

Since 2007, Northern Ireland has operated a Wound Care Formulary across the HSC and the implementation of this Wound Care Formulary has been supported by the Northern Ireland Drug Tariff (part III (g)).

http://www.hscbusiness.hscni.net/pdf/DT_PART_3g-1902.pdf

A consultation was carried out by the Department in relation to proposed changes to the Northern Ireland Drug Tariff in relation to wound care management products.

As a result of the consultation, I am writing to advise that the Northern Ireland Drug Tariff will be populated with the wound care management products, and corresponding reimbursement prices, as listed in Part IXA of the England & Wales Drug Tariff with effect from 1 April 2019.

I would like to reassure colleagues across the HSC that the vast majority of wound care products currently prescribed in primary care will continue to be available for prescribing on HS21 prescription after 1 April 2019 and that **there is no need to change your practice.**

A number of operational issues are currently being progressed to support the new arrangements. The Health and Social Care Board (HSCB) will issue further

communication in the coming weeks in relation to operational issues arising from this change to the Drug Tariff. Furthermore, the HSCB is currently in the process of updating the Wound Care Formulary and that is due to be completed by end June 2019.

I should be grateful if you could ensure that this letter is disseminated to all relevant individuals within your organisation.

Yours sincerely,



Mrs Cathy Harrison
Acting Chief Pharmaceutical Officer